March 4, 2020 / 1:10 PM / a month ago

BRIEF-Cellect Biotechnology And Canndoc To Enter Into Strategic Pharma Grade Cannabis Commercial Deal For Reduction In Opioid Usage

March 4 (Reuters) - Cellect Biotechnology Ltd:

* CELLECT BIOTECHNOLOGY AND CANNDOC LTD. TO ENTER INTO STRATEGIC PHARMA GRADE CANNABIS COMMERCIAL DEAL FOR REDUCTION IN OPIOID USAGE

* CELLECT BIOTECHNOLOGY LTD - CELLECT WILL LEAD DEVELOPMENT OF FUTURE GENERATIONS OF PHARMA GRADE MEDICAL CANNABIS PRODUCTS

* CELLECT BIOTECHNOLOGY - CELLECT WILL ACQUIRE FROM CANNDOC ALL RIGHTS TO USE OF CANNDOC PRODUCTS FOR REDUCTION OF OPIOID USAGE

* CELLECT BIOTECHNOLOGY LTD - CELLECT WILL HAVE OPTION TO EXTEND AGREEMENT FOR AN ADDITIONAL PERIOD OF 5 YEARS, UNTIL 2029

* CELLECT BIOTECHNOLOGY - CELLECT WILL ISSUE TO CANNDOC 1 MILLION ADRS OF CELLECT’S SHARE CAPITAL ON PARTIALLY DILUTED BASIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below